Aims: Prognostic factors and treatment modalities in chondrosarcoma (CS) remain poorly defined. This study aimed to present our institutional experience with CS patients. Methods: We retrospectively reviewed the medical records of 69 CS patients treated at our Cancer Institute between 2010 and 2023. Results: Median age at diagnosis was 47 years, with a slight male predominance (52%) and a median follow-up of 93 months. Grade 1 (34%) and grade 2 (34%) tumors were most common, predominantly affecting the lower extremities (40%) and pelvis (26%). At presentation, 63 patients had localized disease and 6 had metastases; metastases later developed in 13 additional patients, most frequently in the lungs. All 63 patients with localized disease underwent surgery, and 7 received adjuvant chemotherapy (CT). Recurrence developed in 26 patients, of whom 9 were treated with systemic therapy. Among 6 patients with stage IV disease, 5 underwent palliative surgery and received CT. The most commonly used regimens included doxorubicin based CT, pazopanib, sirolimus, and celecoxib. Among patients who developed metastasis during follow-up, 12/13 died. The median time from diagnosis to metastasis was 17.0 months (95% CI: 10.8–23.1), and median survival thereafter was 21.0 months (95% CI: 12.7–29.2). All six patients metastatic at presentation died, with a median progression-free survival of 7.0 months (95% CI: 2.1–11.8) and OS of 12.0 months (95% CI: 0.0–33.6). OS was 75%, 63%, and 57% at 5, 10, and 15 years, respectively. Female sex, low–intermediate grade, and stage I–II disease correlated with better OS in univariate analysis, but only stage at diagnosis remained significant in multivariate analysis (p=0.002). Conclusion: Our findings highlight that early tumor stage is the only independent predictor of overall survival, underscoring the critical importance of early diagnosis and timely intervention in CS.
Önder et al. (Mon,) studied this question.